Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair

• Xin Peng,
• Yingying Wang,
• Shaolu Zhang,
• Zhennan Tao,
• Yuxiang Dai,
• Francois X. Claret,
• Moshe Elkabets,
• Hou-Wen Lin,
• Zhe-Sheng Chen,
• Dexin Kong

Affiliations

Xin Peng

Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University

Yingying Wang

Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University

Shaolu Zhang

Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University

Zhennan Tao

Department of Neurosurgery, the Affiliated Drum Tower Hospital, School of Medicine, Nanjing University

Yuxiang Dai

Department of Neurosurgery, the Affiliated Drum Tower Hospital, School of Medicine, Nanjing University

Francois X. Claret

Department of Systems Biology, The University of Texas MD Anderson Cancer Center

Moshe Elkabets

The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev

Hou-Wen Lin

Research Center for Marine Drugs, State Key Laboratory of Oncogenes and Related Genes, Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University

Zhe-Sheng Chen

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University

Dexin Kong

Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University